Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis-Reference-Cited by-同舟云学术

Ximelagatran, direct thrombin inhibitor, oral anticoagulants, thromboprophylaxis

Published:2006-01 Issue:1 Volume:2 Page:49-58
ISSN:1176-6344
Container-title:Vascular Health and Risk Management
language:en
Short-container-title:Vascular Health and Risk Management

Author:

Ho Shir-Jing,Brighton Tim A

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Hematology,General Medicine,Endocrinology, Diabetes and Metabolism

Reference38 articles.

1. About This Journal

2. Why Do Patients With Atrial Fibrillation Not Receive Warfarin?

3. Dorani H, Schutzer KM, Sarich TC, etal2004. Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran. Proceedings American Society for Clinical Pharmacology and Therapeutics. 20-24 Jun 2004. Miami Beach, FL, USA.

4. The beginning of the end of warfarin?

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials;Exploratory Research in Clinical and Social Pharmacy;2024-06

2. Utilizing in silico Methods in New Drug Design;Recent Advances in Biotechnology;2024-03-12

3. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism;Cochrane Database of Systematic Reviews;2023-04-14

4. Snake Venom;Snake Venom and Ecology;2022-07-06

5. Potential clinical applications of phytopharmaceuticals for the in‐patient management of coagulopathies in COVID ‐19;Phytotherapy Research;2022-02-11